Phase 2 Stomach Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with stomach cancer or cancer at the junction of the stomach and oesophagus (confirmed by a tissue test), and who have not yet received any cancer treatment for this condition.
• People aged 18 to 70 years old, of any gender.
• People who are able to provide a fresh tumour tissue sample, or a stored tissue sample (preserved in a specific way) taken within the past 6 months.
• People who have biomarker test results available before joining the trial.
• People who are generally well enough to carry out daily activities with little or no limitation (as measured by a standard medical scale called ECOG, score 0 or 1).
• People who are expected to live for at least 6 months.
• People whose liver, kidneys, bone marrow, and other organs are functioning well enough to tolerate treatment.
• Women who are not able to become pregnant, or women who could become pregnant but have a negative pregnancy blood test within 3 days before starting treatment, are not breastfeeding, and agree to use contraception and avoid donating eggs from when they sign consent until 8 months after the last dose; male participants must also agree to use contraception and avoid donating sperm during this period.
• People who are willing to sign a consent form and are able to attend scheduled visits, follow the treatment plan, and complete required tests and procedures.

Who may not be able to join:

• People whose stomach cancer is a different type than adenocarcinoma (such as squamous cell carcinoma, undifferentiated carcinoma, or mixed types).
• People who have lost 20% or more of their body weight in the 2 months before joining the trial.
• People who have previously received cancer treatment for stomach or gastroesophageal junction cancer; who have taken part in another drug trial with a recent dose within 4 weeks or within 5 half-lives of that drug (whichever is longer); who have had major surgery within the past 28 days; or who have received a live vaccine within 28 days before the trial or plan to during or within 60 days after treatment.
• People who have a known allergy or serious reaction to any of the study drugs or to humanised monoclonal antibody medicines (confirm with trial site for full drug list).
• People who have had another cancer in the past 5 years, with some exceptions for certain treated skin cancers, early-stage bladder cancer, cervical carcinoma in situ, a type of early breast condition, or papillary thyroid cancer.
• People with a history of immune system deficiency, organ transplant, or an active autoimmune disease.
• People who have had significant bleeding in the past 3 months, or who have a condition that increases bleeding risk; or who have had a blood clot in an artery or vein in the past 6 months or at the time of screening.
• People with wounds that are not healing, active ulcers, or broken bones that have not been treated.
• People with serious active digestive tract problems.
• People with interstitial lung disease or other significant lung conditions.
• People with serious heart, brain blood vessel, or metabolic conditions.
• People with active hepatitis B or hepatitis C infection, or both at the same time.
• People with active tuberculosis (TB) in the past year, or a history of TB that was never treated.
• People who have had a serious infection in the past 4 weeks, or a significant active infection requiring antibiotic treatment in the past 2 weeks, or ongoing infections that could affect treatment or surgery.
• People with a history of drug or substance misuse.
• People who, in the opinion of the trial doctor, have any other condition that could increase risk, affect the trial results, or make participation unsuitable.

Important: Always verify eligibility with the trial site directly before applying.